Join the Semaglutide group to help and get support from people like you.
Semaglutide News
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 – For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with...
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers
WEDNESDAY, May 28, 2025 — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says. People taking a ...
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 – Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in confirmatory trials, with a...
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
FRIDAY, May 23, 2025 — A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on. The U.S. Food and Drug A...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 – For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric...
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
TUESDAY, May 13, 2025 — Cutting-edge weight-loss drugs like Ozempic/Wegovy can cut alcohol intake dramatically in a short amount of time, a new study says. People taking semaglutide or liraglutide r...
GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity
MONDAY, May 12, 2025 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and...
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
FRIDAY, May 2, 2025 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study...
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 – The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 – After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without...
FDA Medwatch Alert: FDA Warns Consumers Not to Use Counterfeit Ozempic (semaglutide) Found in U.S. Drug Supply Chain
April 14, 2025 – FDA was notified by Novo Nordisk on April 3, 2025, that several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg were in the U.S. drug supply chain. The counterfeit...
Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes
TUESDAY, April 8, 2025 – For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published...
ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
WEDNESDAY, April 2, 2025 – For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased walking distance, according to a study published...
Tirzepatide, Semaglutide Not Cost-Effective at Current Prices
WEDNESDAY, March 19, 2025 – Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health Forum. Jennifer H....
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
TUESDAY, March 18, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2